• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Tilray Will Quintuple Its Medical Marijuana Production In Germany With New Cultivation License

    7/22/24 1:05:39 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $TLRY alert in real time by email

    Tilray Brands, Inc. (NASDAQ:TLRY) (TSX:TLRY) announced on Monday that its Germany cannabis cultivation facility, Aphria RX GmbH, has obtained the first new cannabis cultivation license issued under MedCanG, Germany's new Cannabis Act.

    Why It Matters

    The new cannabis cultivation license allows Aphria RX to cultivate and manufacture a broad commercial range of medical cannabis, providing patients with better access to high-quality medical cannabis produced in Germany.

    Denise Faltischek, the company's chief strategy officer and head of international, explained that the license allows Tilray to expand the range of treatment options available to patients. "We appreciate the trust that the German Government has placed in Tilray, and we are proud of our team for their groundbreaking work in medical cannabis cultivation and patient care," Faltischek said.

    Read Also: Another Cannabis Pioneer Expands In Germany Via Acquisition As Experts Say ‘There’s No Stepping Back’ From Legalization Wave

    Aphria RX was awarded the most comprehensive license for the cultivation of medical cannabis in Germany from the German Federal Institute for Drugs and Medical Devices in May 2019. It was awarded a total of five lots (1,000 kgs) and was the only licensed producer in Germany with permission to grow all three strains of medical cannabis approved by the BfArM.

    Tilray finalized its first harvest of medical cannabis grown in Germany via its German subsidiary Aphria RX in mid-2021. The medical cannabis was distributed to pharmacies in Germany on behalf of the German Cannabis Agency under the country's pharmaceutical and narcotic legal requirements.

    What's Next

    With the new cannabis license, Tilray can fully utilize and maximize its growing capacity while also expanding its genetics to 31 approved strains from the previously approved three strains.

    In the meantime, the new German law on recreational cannabis went into effect on April 1, partially legalizing cannabis by allowing adults over 18 to possess up to 25 grams of dried cannabis and grow three marijuana plants at home.

    Cannabis clubs became legal in Germany on July 1, 2024, ahead of the opening of the first marijuana social club a week later. Lower Saxony Minister of Agriculture Miriam Staudte announced in early July that the permit was awarded by her office to Social Club Ganderkesee.

    Read Next:

    • Aurora & Tilray Better Positioned Than Other Cannabis Operators For Germany’s Imminent Market Launch, Here’s Why

    To learn more about cannabis innovation, com, join us at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. Get your tickets now before prices surge by following this link.

    Get the next $TLRY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TLRY

    DatePrice TargetRatingAnalyst
    4/5/2024$2.25 → $2.75Neutral
    Alliance Global Partners
    11/2/2022$3.90Mkt Perform
    Bernstein
    7/29/2022$3.00Hold → Sell
    The Benchmark Company
    3/4/2022$9.00Hold → Buy
    Canaccord Genuity
    1/11/2022$7.40 → $6.90Neutral
    Cantor Fitzgerald
    1/7/2022$11.80 → $7.40Neutral
    Cantor Fitzgerald
    11/18/2021$10.00Underweight
    Barclays
    11/1/2021$18.00 → $11.80Overweight → Neutral
    Cantor Fitzgerald
    More analyst ratings